{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:17:26Z","timestamp":1792045046591,"version":"4.4.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,11]]},"DOI":"10.1097\/01.bpo.0000176162.78980.ed","type":"journal-article","created":{"date-parts":[[2005,10,21]],"date-time":"2005-10-21T08:00:50Z","timestamp":1129881650000},"page":"786-791","source":"Crossref","is-referenced-by-count":97,"title":["Impact of Alendronate on Quality of Life in Children With Osteogenesis Imperfecta"],"prefix":"10.1097","volume":"25","author":[{"given":"Mouin G","family":"Seikaly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sashi","family":"Kopanati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Salhab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Waber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Browne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A","family":"Herring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-16-20210227","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jmg.16.2.101","article-title":"Genetic heterogeneity in osteogenesis imperfecta.","volume":"16","author":"Sillence","year":"1979","journal-title":"J Med Genet"},{"key":"R3-16-20210227","doi-asserted-by":"crossref","first-page":"433","DOI":"10.18388\/abp.2002_3802","article-title":"Mutations in type I collagen genes resulting in osteogenesis imperfecta in humans.","volume":"49","author":"Gajko-Galicka","year":"2002","journal-title":"Arch Biochim Pol"},{"key":"R4-16-20210227","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2165\/00128072-200002060-00005","article-title":"Osteogenesis imperfecta practical treatment guidelines.","volume":"2","author":"Antoniazz","year":"2000","journal-title":"Pediatr Drugs"},{"key":"R5-16-20210227","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00003086-197306000-00024","article-title":"New approaches to treatment of osteogenesis imperfecta.","volume":"93","author":"Castells","year":"1973","journal-title":"Clin Orthop"},{"key":"R6-16-20210227","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(04)16051-0","article-title":"Osteogenesis imperfecta.","volume":"363","author":"Rauch","year":"2004","journal-title":"Lancet"},{"key":"R7-16-20210227","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1258\/0004563011901037","article-title":"Bisphosphonate: overview with special reference to alendronate.","volume":"38","author":"Vasikaran","year":"2001","journal-title":"Ann Clin Biochem"},{"key":"R8-16-20210227","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/BF00350961","article-title":"Radiological manifestation of bisphosphanate treatment with APD in a child suffering from osteogenesis imperfecta.","volume":"16","author":"Devoglear","year":"1987","journal-title":"Skeletal Radiol"},{"key":"R9-16-20210227","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclical administration of pamidronate in children with severe osteogenesis imperfecta.","volume":"339","author":"Glorrieux","year":"1998","journal-title":"N Engl J Med"},{"key":"R10-16-20210227","first-page":"1846","article-title":"Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age.","volume":"85","author":"Plotkin","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"R11-16-20210227","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1136\/adc.86.5.356","article-title":"Beneficial effect of long-term intravenous bisphosphonate treatment of osteogenesis imperfecta.","volume":"86","author":"Astrom","year":"2002","journal-title":"Arch Dis Child"},{"key":"R12-16-20210227","doi-asserted-by":"crossref","first-page":"9943","DOI":"10.1053\/apmr.2001.23889","article-title":"Osteogenesis imperfecta in childhood: perceived competence in relation to impairment and disability.","volume":"82","author":"Engelbert","year":"2001","journal-title":"Arch Phys Med Rehabil"},{"key":"R13-16-20210227","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1203\/00006450-200211000-00010","article-title":"Alendronate treatment for infants with osteogenesis imperfecta; demonstration of efficacy in a mouse model.","volume":"52","author":"Maccarthy","year":"2002","journal-title":"Pediatr Res"},{"key":"R16-16-20210227","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1542\/peds.58.2.259","article-title":"A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine.","volume":"58","author":"Schwartz","year":"1976","journal-title":"Pediatrics"},{"key":"R17-16-20210227","first-page":"921","article-title":"Use of bisphosphonates in children and adolescents.","volume":"5","author":"Allgrove","year":"2002","journal-title":"J Pediatr Endocrinol Metab"},{"key":"R19-16-20210227","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1172\/JCI0215952","article-title":"The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta.","volume":"110","author":"Rauch","year":"2002","journal-title":"J Clin Invest"},{"key":"R20-16-20210227","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1210\/jc.2002-021371","article-title":"Osteogenesis imperfecta type I, III and IV: effect of pamidronate therapy on bone and mineral metabolism.","volume":"88","author":"Rauch","year":"2003","journal-title":"J Clin Endrocinol Metab"},{"key":"R21-16-20210227","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMp038103","article-title":"Do bisphosphonates make childrens bone better?","volume":"349","author":"Marini","year":"2003","journal-title":"N Engl J Med"},{"key":"R22-16-20210227","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1056\/NEJMoa023110","article-title":"Bisphosphonate-induced osteopetrosis.","volume":"349","author":"Whyte","year":"2003","journal-title":"N Engl J Med"},{"key":"R23-16-20210227","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S8756-3282(01)00619-6","article-title":"Targeted and non-targeted remodeling.","volume":"30","author":"Burr","year":"2002","journal-title":"Bone"},{"key":"R24-16-20210227","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s002230010045","article-title":"A controlled study of the effect of alendronate in a growing mouse model of osteogenesis imperfecta.","volume":"69","author":"Camacho","year":"2001","journal-title":"Calcif Tissue Int"},{"key":"R25-16-20210227","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(04)16101-1","article-title":"Skeletal effects of functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo control study.","volume":"363","author":"Sakkers","year":"2004","journal-title":"Lancet"},{"key":"R26-16-20210227","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S8756-3282(02)00974-2","article-title":"Alendronate affects long bone length and growth plate morphology in the oim mouse model for osteogenesis imperfecta.","volume":"31","author":"Evans","year":"2003","journal-title":"Bone"},{"key":"R27-16-20210227","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1210\/jc.2003-030106","article-title":"Improvement of bone in patients with osteogenesis imperfecta treated with pamidronate: lessons from biochemistry.","volume":"88","author":"Langman","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"R28-16-20210227","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0277-9536(94)90294-1","article-title":"The displacement process.","volume":"38","author":"Verbrugge","year":"1994","journal-title":"Soc Sci Med"},{"key":"R29-16-20210227","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1172\/JCI119491","article-title":"Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells.","volume":"99","author":"Izhizuya","year":"1997","journal-title":"J Clin Invest"}],"container-title":["Journal of Pediatric Orthopaedics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00004728-200511000-00028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T05:16:53Z","timestamp":1683263813000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01241398-200511000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1097\/01.bpo.0000176162.78980.ed","relation":{},"ISSN":["0271-6798"],"issn-type":[{"value":"0271-6798","type":"print"}],"subject":[],"published":{"date-parts":[[2005,11]]}}}